Amphetamine is an indirect dopamine receptor agonist and increases glutamate release in the striatum. Activation of group I metabotropic glutamate receptors (mGluRs) upregulates cAMP response element-binding protein (CREB
) and activates mitogen-activated protein kinases (MAPK) (Choe and Wang 2001) . In contrast, activation of group II/III receptors downregulates the adenylate cyclase (AC) and cyclic adenosine monophosphate (cAMP) cascades. Previous studies show that mGluRs are involved in the regulation of amphetamine-induced behaviors in a subgroup specific manner (Cartmell et al. 1999 (Cartmell et al. , 2000 Wang 1999, 2000; Spooren et al. 2000) .
Cyclic AMP response element-binding protein (CREB) and Elk-1 are major transcriptional regulators in striatal projection neurons and are phosphorylated by one member of MAPK family: extracellular signal-regulated kinase 1/2 (ERK1/2) (Sgambato et al. 1998; Vanhoutte et al. 1999) . Stimulation of group I mGluRs with the selective agonist, 3,5-dihydroxyphenylglycine (DHPG), upregulates CREB, Elk-1, and ERK1/2 phosphorylation in the dorsal striatum (Choe and Wang 2001) . Like DHPG, amphetamine increases CREB phosphorylation in the striatum (Konradi et al. 1994) . Numerous studies show that CREB is necessary for c-fos mRNA induction by amphetamine, and Fos protein is induced by glutamatergic signals (Konradi et al. 1994; Vanhoutte et al. 1999) . A recent study also shows that cocaine or methamphetamine increases pERK1/2 immunoreactivity (IR) in the striatum (Adams et al. 2001 ). These findings suggest that both dopaminergic and glutamatergic inputs are capable of regulating the ERK1/2 signaling pathways leading to the phosphorylation of CREB and Elk-1 and thus gene expression in striatal neurons. However, the role of mGluRs in regulating ERK1/2 pathways leading to CREB and Elk-1 phosphorylation in response to dopamine stimulation remains to be documented.
In this study, potential roles of group I mGluRs were therefore examined by investigating whether amphetamine upregulates CREB, Elk-1 and ERK1/2 phosphorylation and Fos expression via a group I mGluRdependent way in striatal neurons. Experiments were performed in freely moving rats treated with: (1) an acute injection of amphetamine; (2) intrastriatal infusion of the group I selective antagonist, n-phenyl-7-(hydroxyimino) cyclopropa [b] chromen-1a-carboxamide (PHCCC), followed by an acute amphetamine injection; (3) intrastriatal infusion of the group II/III selective antagonist, (RS)-␣ -methylserine-o-phosphate monophenyl ester (MSOPPE), followed by an acute amphetamine injection; (4) systemic injection of the mGluR5 selective antagonist 2-methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP), followed by an acute amphetamine injection; and (5) intrastriatal infusion of the ryanodine receptor antagonist, dantrolene, followed by an acute amphetamine injection. Immunohistochemistry and Western blot were applied to quantify alterations in the levels of the phosphorylated or unphosphorylated signaling molecules in the selected areas of ipsilateral dorsal striatum.
METHODS

Animals
Adult male Wistar rats (200-250 g) were obtained from Charles River Laboratories (New York, NY). Rats were individually housed in a controlled environment during all experimental treatments. Food and water were provided ad libitum and rats were maintained on a 12/12-h light/dark cycle (lights on at 7:00 A . M .). On the day of the experiment injection was made in the quiet room to minimize stress. All animal use procedures were approved by the Institutional Animal Care and Use Committee and were accomplished in accordance with the provisions of the NIH Guide for the Care and Use of Laboratory Animals.
Drugs
All pharmacological drugs were purchased from Tocris Cookson (Ballwin, MO) except for D-amphetamine (Sigma, St. Louis, MO) and freshly prepared on the day of the experiment. PHCCC, MSOPPE, MPEP, and dantrolene were dissolved in dimethylsulfoxide (DMSO), and then diluted in artificial cerebrospinal fluid (aCSF) (in mM: NaCl 123, CaCl 2 0.86, KCl 3.0, MgCl 2 0.89, NaH 2 PO 4 0.50 and Na 2 HPO 4 0.25 aerated with 95% O 2 /5% CO 2 , pH 7.2-7.4). Amphetamine was directly dissolved in 0.9% saline. DMSO in combination with aCSF was therefore used as vehicle control for the respective agents. Solutions of all drugs were neutralized to pH 7.2-7.4 with 1N NaOH, if necessary.
Experimental Design
Five separate experiments were conducted in this study. The first and second experiments investigated whether amphetamine upregulates the phosphorylation of MAPKs (ERK1/2 and p38) and downstream transcription factors CREB and Elk-1 using immunohistochemistry and Western blot. Rats were randomly divided into two groups (n ϭ 4-5 per group). Each rat received one intraperitoneal (i.p.) injection of saline or amphetamine (5 mg/kg). The third experiment detected whether group I mGluRs mediate amphetamine-stimulated CREB, Elk-1 and ERK1/ 2 phosphorylation and Fos induction using immunohistochemistry. Rats were randomly divided into six groups (n ϭ 4-5 per group). PHCCC (25 nmol) or MSOPPE (25 nmol) was infused into the center of the striatum 30 min prior to an acute amphetamine injection (5 mg/kg, i.p.). The fourth experiment examined whether mGluR5, a group I subtype that is highly expressed in medium spiny projection neurons (Testa et al. 1994) , participates in the mediation of amphetamine actions. Effects of the systemically active mGluR5 antagonist MPEP (i.p. injection; 30 min prior to amphetamine) on amphetamine ac-tions were tested in different groups of rats (n ϭ 4 per group). Finally, a fifth experiment was conducted to evaluate the role of intracellular Ca 2 ϩ release in the group I-sensitive signaling pathway regulating the phosphoproteins. Group I mGluRs are known to stimulate phospholipase C resulting in increased 1,4,5-triphosphate (IP 3 ). IP 3 could then stimulate IP 3 receptors on internal Ca 2 ϩ stores to release Ca 2 ϩ . However, at present, agents that interact with IP 3 receptors are not suitable for the in vivo study due to the lack of permeability in intact cells and characterizations (such as heparin). We then used a systemically active and membrane-permeable agent dantrolene to test the possible participation of ryanodine receptorsensitive Ca 2 ϩ release to amphetamine actions. Dantrolene (2 or 20 nmol) that blocks intracellular Ca 2 ϩ release from the ryanodine-sensitive stores was infused into the center of the striatum 30 min prior to an acute amphetamine injection in different groups of rats (n ϭ 4-5 per group). The selection of 20 nmol of dantrolene was based on our previous finding that intracaudate injection of the agent at this dose was able to attenuate DHPG-stimulated motor activity . This indicates a role of ryanodine-sensitive Ca 2 ϩ release in behavioral effects of DHPG, even though group I mGluRs are considered to be directly linked to IP 3 -sensitive Ca 2 ϩ release.
Surgery and Intrastriatal Injection
Rats were anesthetized with 8% chloral hydrate (5.8 ml/ kg, i.p.) and placed in a Kopf stereotaxic apparatus. Under aseptic conditions, a 23-gauge stainless steel guide cannula (inner diameter: 0.29 mm, 10 mm in length) was implanted at the coordinates of 1 mm anterior to bregma, 2.5 mm right to midline, and 3 mm below surface of skull. The guide cannula was sealed with a stainless steel wire of the same length (10 mm). Rats were allowed five days to recover from surgery. On the day of the experiment, the inner steel wire was replaced by a 30-gauge stainless steel injection cannula (inner diameter: 0.15 mm) with a length of 12.5 mm that protruded 2.5 mm beyond the guide cannula. Through the injection cannula drug was infused unilaterally into the central part of the right dorsal striatum in a volume of 1 l at a rate of 0.2 l/min in freely moving rats. Progress of injection was monitored by observing movement of a small air bubble through a length of precalibrated PE-10 tubing inserted between the injection cannula and a 2.5 l Hamilton microsyringe. After completion of injection, the injector was left in place for an additional 5 min to reduce any possible backflow of the solution along the injection tract. All injections were made in home cage.
Western Blot
Rats were deeply anesthetized with Equithesin (5 ml/ kg, i.p.) and decapitated 30 min after saline or amphetamine injection. Brains were removed and frozen in isopentane at Ϫ 40 Њ C and stored in a deep freezer. Sixty micrometer sections were cut in a cryostat and overall dorsal striatum was removed with a steel borer (inner diameter: ‫ف‬ 2 mm). Three tissue samples per brain were lysed in SDS sample buffer for 5 min at 95 Њ C. The samples were then sonicated for 30 s on ice and centrifuged for 10 min at 14,000 rpm with an Eppendof tabletop centrifuge. The supernatants were resolved using 10% SDS-PAGE and transferred to nitrocellulose membrane. The membrane was blocked with blocking buffer (0.1% gelatin, 15 mM Tris-HCl, pH7.5, 1 mM EDTA, 0.1% Triton X-100, 130 mM NaCl, and 0.002% NaN 3 ). The membrane was probed with each primary antibody overnight at room temperature: pCREB (1:2,000), CREB (1:2,000), pERK1/2 (p-p44/42 MAPK, 1:2,000), ERK1/2 (1:2,000), p-p38 MAPK (1:2,000), and p38 MAPK (1:2,000). All of the primary antibodies were purchased from Cell Signaling Technology (Beverly, MA). The membrane was then incubated with appropriate secondary antibodies. Unphosphorylated proteins were probed after stripping the same membrane that has been probed for phosphorylated proteins. Immunoreactive protein bands were detected by enhanced chemiluminescence reagents (ECL; Amersham Pharmacia Biotech, Piscataway, NJ) on an X-ray film.
Immunohistochemistry
Thirty minutes after the final injection, rats were deeply anesthetized with Equithesin (5 ml/kg, i.p.), and transcardially perfused with 4% paraformaldehyde at 4 Њ C. The 30-min survival time was chosen based on previous studies on the kinetics of CREB phosphorylation in vivo McGinty 2000, 2001) . Brains were removed and postfixed in 10% sucrose/4% paraformaldehyde for 2 h at 4 Њ C and then placed in 20% sucrose/PBS at 4 Њ C overnight. Using a cryostat microtome, 40 m frozen sections were cut. Two sections per antiserum per brain were collected at striatal levels and processed for immunohistochemistry. P-CREB antiserum (1:1,000) recognizes the CREB phosphoprotein surrounding amino acid Ser133. P-Elk-1 antiserum (1:6,000) detects Elk-1 protein only when phosphorylated at amino acid Ser383. P-p44/42 MAPK antiserum (1:500) detects ERK1 and ERK2 only when catalytically activated by phosphorylation at Thr202 and Tyr204. All of the primary antibodies listed above were purchased from Cell Signaling Technology. Sections were incubated with each antiserum for 20 h at 4 Њ C on a shaker. Sections were then incubated in goat Semi-quantitative analysis showed that amphetamine significantly increased pCREB (C), pElk-1 (F), and pERK1/2 (I) immunoreactivity in striatal neurons (n ϭ 4-5 per group). *p Ͻ .001 as compared with saline groups.
anti-rabbit secondary antiserum (Vector Labs, Burlingame, CA) for 1 h followed by avidin-biotin-peroxidase reagents (Elite Vectastain kit, Vector Labs) for 1 h at room temperature. Diaminobenzidine was used as the chromagen and NiCl 2 was added to enhance reaction product. In previous studies, the pCREB, pElk-1, pERK1/2, or Fos antiserum was adsorbed with pCREB, pElk-1, pERK1/2, or Fos peptide and immunostaining was blocked (Simpson et al. 1995; Choe and McGinty 2000) . As a control for pCREB-IR, CREB-IR was not induced by a cAMP analog or group I mGluR agonist (Choe and McGinty 2000; Choe and Wang 2001) .
Quantitation of Immunoreactivity
Immunoreactive protein bands on X-ray films were semi-quantified using an Imaging CCD camera and NIH Image 1.62 software. Briefly, film background was measured and saved as a "blank field" to correct uneven illumination. The upper limit of the density slice option was set to eliminate any background, and this value was used to measure all images. The lower limit was set at the bottom of the LUT scale. The immunoreactive protein bands were measured using a rectangle covered the individual band. Similarly, levels of pCREB, pElk-1, pERK1/2, or Fos IR in the dorsal striatum were semi-quantified using a modified procedure from Simpson et al. (1995) . Briefly, immunoreactive images were captured from a Nikon photomicroscope using an Imaging CCD camera and NIH Image 1.62 software. For the first and fourth experiment, using a 10x objective, the immunoreactivity in two sections per brain stained with each antiserum was measured in a 640 ϫ 480 pixel area in the right dorsal striatum (rectangle A in Figure 1 ). For the second, third, and fifth experiments, a 480 ϫ 300 pixel area was used to measure the immunoreactivity of the markers in the medial or lateral areas of the ipsilateral dorsal striatum (rectangles M and L in Figure 1 ). The areas analyzed for quantification were held constant for all experiments. The density threshold was adjusted so that background staining in white matter regions was eliminated and the number of immunoreactive pixels per selected area was measured above this threshold. The number of immunoreactive pixels represents all counted pixels over all positive staining cells in an area surveyed, which closely reflects changes in the number of cells immunoreactive to a given marker.
Statistics
Statistical significance of the number of immunoreactive pixels per measured area between groups was determined using a 1-way ANOVA on ranked data followed by a Tukey's HSD (honestly significant difference) test in SAS (Cary, NC). Statistically significant level was taken as p Ͻ .05. was significantly increased by a single amphetamine injection. However, p-p38 MAPK IR was not altered by amphetamine (Figure 3, panel C) . We have attempted to perform Western blot with anti-Elk-1 antisera. However, the data revealed that these antisera were not suitable for the immunoblotting.
PHCCC, But Not MSOPPE, Attenuated
Amphetamine-stimulated pCREB, pElk-1, pERK1/2, and Fos Immunoreactivity Since amphetamine phosphorylated CREB, Elk-1, and ERK1/2, the group I (PHCCC) or group II/III antagonist (MSOPPE) was infused intrastriatally to test whether group I mGluRs couple amphetamine to CREB, Elk-1, ERK1/2 phosphorylation and Fos induction in the striatum. Fos was added in this experiment to detect concurrent changes in inducible gene expression as a result of the induction of phosphoproteins. In the medial region of the striatum, low basal levels of pCREB (Figure 4 , panel A), pElk-1 (Figure 4 , panel E), and Fos (Figure 4 , panel M) IR were seen in rat received saline. Neither PH-CCC nor MSOPPE infusion alone altered basal levels of pCREB, pElk-1, and Fos IR. P-ERK1/2 IR was not detected in rat treated with saline ( Figure 4 In contrast to PHCCC, MSOPPE did not alter amphetamine-induced increases in the immunoreactivity of all the 4 markers. Like pCREB and pElk-1 IR, Fos IR induced by amphetamine was exclusively confined to the nuclear compartments of striatal neurons. Semi-quantitation confirmed that amphetamine increased the immunoreactivity of all the markers in the medial striatum, which was blocked by pretreatment with PHCCC, but not MSOPPE (Figure 4 , panels D, H, L, and P). Similar results were obtained in the lateral region of the striatum, which are illustrated in Figure 5 .
MPEP Attenuated Amphetamine-stimulated pCREB, pElk-1, pERK1/2, and Fos Immunoreactivity
A separate study was carried out to evaluate the importance of mGluR5 in the amphetamine action. From Figure 6 , i.p. injection of MPEP alone at the two doses (1 and 10 mg/kg) had no significant effects on basal levels of pCREB, pElk-1, pERK1/2, and Fos IR in the dorsal striatum. MPEP at the lower dose (1 mg/kg) did not alter amphetamine-stimulated phosphorylation of the three phosphoproteins and Fos induction in the dorsal striatum. However, MPEP at the higher dose (10 mg/ kg) significantly attenuated pCREB, pElk-1, pERK, and Fos IR induced by amphetamine. Dantrolene Did Not Alter Amphetamine-stimulated pCREB, pElk-1, pERK1/2, and Fos Immunoreactivity Ryanodine receptors are known to mediate intracellular Ca 2ϩ release that may participate in the regulation of CREB, Elk-1 and ERK1/2 phosphorylation and Fos induction in response to amphetamine stimulation. In this study, dantrolene (2 or 20 nmol) that blocks intracellular Ca 2ϩ release from ryanodine-sensitive stores was infused into the dorsal striatum to evaluate whether ryanodine-sensitive stores couple amphetamine to CREB, Elk-1, and ERK1/2 phosphorylation and Fos induction in the striatum, and the results from semi-quantitative analysis are shown in Figure 7 . Saline or 20 nmol dantrolene alone had no effect on basal levels of pCREB, pElk-1, pERK1/2, and Fos IR. Neither 2 nor 20 nmol dantrolene altered amphetamine-induced increases in pCREB, pElk-1, pERK1/2, and Fos IR in both medial and lateral regions of the striatum.
DISCUSSION
In the present study, acute amphetamine increased the phosphorylation of CREB, Elk-1, ERK1/2 and Fos gene expression in the striatum. Since the phosphorylation was attenuated by the group I mGluR antagonist PH-CCC as well as the mGluR5 antagonist MPEP, activation of group I mGluRs is important for a full capacity of amphetamine to phosphorylate these signaling proteins. The calcium release from ryanodine-sensitive stores did not seem to play a significant role in this event because the ryanodine receptor antagonist dantrolene was ineffective to alter amphetamine effects.
The present results showed that amphetamine increased the immunoreactivity of pCREB, pElk-1, and pERK1/2 in the striatum. Previous studies demonstrate that amphetamine increases the phosphorylation of CREB in the striatum (Konradi et al. 1994 ). The AC activator, forskolin, and cAMP analogs activate the ERK1/ 2 cascades in hippocampal and striatal neurons (Vossler et al. 1997; de Rooij et al. 1998; Kawasaki et al. 1998; Vincent et al. 1998; Impey et al. 1998; Choe and McGinty 2000) . A recent study shows that cocaine or methamphetamine upregulates pERK1/2 IR in the striatum (Adams et al. 2001) . These findings suggest that dopamine stimulation is capable of activating the ERK1/2 signaling pathway, which may be involved in subsequent facilitation of CREB and Elk-1 phosphorylation.
In addition to dopamine (D 1 ) receptors, activation of group I mGluRs increases ERK1/2 phosphorylation in the spinal cord (Karim et al. 2001) , primary astrocytes (Schinkmann et al. 2000) , glial cell cultures (Peavy and Conn 1998) , and the striatum (Choe and Wang 2001) . Similarly, mGluR1a mediates phosphorylation of ERK2 in Chinese hamster ovary cells transfected with rat mGluRs (Ferraguti et al. 1999 ) and rat cortical cultures (Fiore et al. 1993) . ERK1/2 has been found to be a major kinase phosphorylating CREB and Elk-1. For instance, ERK cascades couple CREB phosphorylation in CA1 area of hippocampus (Roberson et al. 1999 ). Activation of ERK1/2 by Ca 2ϩ influx increases CREB phosphorylation in PC12 cells and hippocampal neurons (Impey et al. 1998) . ERK1/2 is also found to mediate glutamateinduced phosphorylation of transcription factors because the ERK1/2 kinase inhibitor, PD98059, attenuates glutamate-stimulated CREB and Elk-1 phosphorylation in striatal slices (Vanhoutte et al. 1999 ) and the striatum (Sgambato et al. 1998; Davis et al. 2000; Choe and McGinty 2001) . Thus, in striatal neurons, ERK1/2 may represent an effector downstream to glutamate receptors that phosphorylates transcription regulators CREB and Elk-1. In this study, blockade of group I mGluRs by PHCCC decreased amphetamine-stimulated pCREB, pElk-1, pERK1/2, and Fos IR in both medial and lateral areas of the striatum. In contrast, blockade of group II/ III mGluRs did not affect the immunoreactivity of all the markers. Thus, group I mGluR-sensitive ERK1/2 activation may participate in the amphetamine-stimulated pCREB and pElk-1 induction. Further studies are needed to test effects of the blockade of ERK1/2 activation with PD98059 on the amphetamine phosphorylation of CREB/Elk-1 in order to provide direct evidence to argue for or against this notion.
Parallel to upregulation of pCREB and pElk-1 induction, Fos induction was increased in this study, suggesting a possible transcriptional role of pCREB and pElk-1 in inducible c-fos gene expression. This is supported by the finding that knock down of CREB by antisense oligonucleotides against CREB attenuates c-fos induction in the striatum in vivo (Konradi et al. 1994) .
Blockade of intracellular Ca 2ϩ release from ryanodine-sensitive stores by dantrolene did not affect amphetamine-stimulated pCREB, pElk-1, pERK1/2, and Fos IR in both medial and lateral regions of the dorsal striatum. These data indicate that intracellular Ca 2ϩ release from ryanodine-sensitive stores may not be involved in amphetamine-stimulated increases in the regulatory proteins of ERK1/2 pathways. It is therefore possible that Ca 2ϩ release from IP 3 -sensitive stores and/or enhanced Ca 2ϩ influx via NMDA receptors or L-type voltage-operated Ca 2ϩ channels may contribute to the activation of ERK1/2 pathways in the striatum. This is supported by the findings that stimulation of mGluR1a potentiates N-methyl-D-Aspartate (NMDA) channel activity through protein kinase C (Alagarsamy et al. 1999; Hisatsune et al. 1997; Choe and Wang 2002) . NMDA receptor activation phosphorylates ERK1/2 or CREB, which is prevented by NMDA receptor blockade in cultured rat cortical (Jiang et al. 2000) or striatal (Das et al. 1997 ) neurons and rat hippocampus (Ahn et al. 2000) .
In summary, the results obtained from this study and others indicate a glutamate receptor scenario in mediating amphetamine effects on signaling proteins and gene expression. This scenario initiates with in- Figure 7 . Semi-quantitative analysis of the effect of intrastriatal infusion of 2 or 20 nmol dantrolene on an acute amphetamine-stimulated pCREB (A), pElk-1 (B), pERK1/2 (C), and Fos (D) immunoreactivity in the medial and lateral areas of the striatum (n ϭ 4-5 per group). Intrastriatal dantrolene was given alone or 30 min prior to amphetamine (5 mg/kg, i.p.). Neither 2 nor 20 nmol dantrolene altered amphetamine (AMPH, 5 mg/kg, i.p.)-stimulated immunoreactivity of all the markers. *p Ͻ .001 as compared with saline group. creased glutamate release in the striatum after amphetamine stimulation (Del Arco et al. 1999; Nash and Yamamoto 1993; Rawls and McGinty 2000 
